Novo Offers up to $2.1B for Omeros’ Complement Drug To Expand Rare Disease Work

By /

Novo Nordisk struck another deal, this time with Omeros, amid a broader pipeline restructuring that recently claimed its cell therapy work.

Scroll to Top